Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) has decided to add two new clinical trial sites in its portfolio. According to reports, the Medical College of Wisconsin has been added to the new site for Invivo’s IDE pilot study. It focuses on those patients who have Neuro-Spinal Scaffold.
Insights On The Matter:
Currently, Froedtert Hospital doesn’t have anything else than the adult Level 1 trauma center in eastern Wisconsin. During the times of emergency, it receives patients on referral basis from northern Michigan as well as Northern Illinois. Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) has decided to use vast experience of Shekar Kurpad in the management. According to reports, he has been appointed as the Principal Investigator at the newly launched site.
Dr. Kurpad comes with a Ph.D. degree. Currently, he works as the professor of neurosurgery at MCW. Apart from this, he also works as the director of the Spine Surgery Fellowship and spinal cord injury center at the Froedtert Hospital. The entire management team is excited to announce the name of the new trial sites. Dr. Kurpad stated that it’s one of the unique and first-of-its-kind steps taken by the company. According to him, each member of the management team is excited to work together on this project.
Year 2015, has brought a lot of proud moments for the company. A few days ago on January 22, 2015, it announced that one patient had enrolled himself at the Carolinas Medical Center in Charlotte for trial study. In total, it was the second time when someone had given his name for the study at the trial site. The first incident took place on October 2014 when a patient enrolled himself for the study at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. The Barrow Neurological Institute of this hospital was the only trial site equipped with the latest amenities back then.